# Béla Merkely

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bela-merkely/

## Facts

| Field | Value |
| --- | --- |
| Citations | 118,698 |
| Field | Cardiovascular Function and Risk Factors |
| h-index | 107 |
| i10-index | 646 |
| Last Known Institution | Semmelweis University |
| OpenAlex ID | https://openalex.org/A5086692319 |
| ORCID iD | 0000-0001-6514-0723 |
| Works | 1,966 |

## Researcher papers

Showing 12 of 23.

- [2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)](https://scholariq.org/papers/2020-esc-guidelines-for-the-diagnosis-and-management-of-atrial-fibrillation/)
- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-2/)
- [Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure](https://scholariq.org/papers/cardiovascular-and-renal-outcomes-with-empagliflozin-in-heart-failure/)
- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-heart-failure-with-mildly-reduced-or-preserved-ejection/)
- [ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-4/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity](https://scholariq.org/papers/semaglutide-in-patients-with-heart-failure-with-preserved-ejection-fraction-and/)
- [Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation](https://scholariq.org/papers/dual-antithrombotic-therapy-with-dabigatran-after-pci-in-atrial-fibrillation/)
- [Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization](https://scholariq.org/papers/prasugrel-versus-clopidogrel-for-acute-coronary-syndromes-without/)
- [Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/)

## Researcher topics

- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Cardiac Arrhythmias and Treatments](https://scholariq.org/topics/cardiac-arrhythmias-and-treatments/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [Semmelweis University](https://scholariq.org/institutions/semmelweis-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.